FDA ex­perts of­fer a unan­i­mous en­dorse­ment for Spark’s pi­o­neer­ing AAV gene ther­a­py for blind­ness

Kather­ine High, head of R&D, Spark Ther­a­peu­tics

A pi­o­neer­ing AAV gene ther­a­py from Spark Ther­a­peu­tics $ONCE took a gi­ant stride to­ward an FDA ap­proval to­day as an out­side pan­el of ex­perts of­fered their sup­port for get­ting this game-chang­ing treat­ment in­to the mar­ket af­ter look­ing over the da­ta and hear­ing from some of the se­vere­ly sight-im­paired pa­tients whose lives had been trans­formed by this ther­a­py.

The vote was 16 to o fa­vor­ing the ben­e­fit-risk pro­file of the drug, back­ing an OK for voreti­gene nepar­vovec by the agency’s Cel­lu­lar, Tis­sue and Gene Ther­a­pies Ad­vi­so­ry Com­mit­tee and pro­vid­ing a com­pelling rea­son for the FDA to fol­low through with an his­toric first US ap­proval of a vec­tor-de­liv­ered gene ther­a­py.

“Gene ther­a­py has made my world so much more brighter,” said one young pa­tient, who went on to de­scribe how he could see the moon for the first time, go out at night, watch fa­cial ex­pres­sions, and ba­si­cal­ly live his life more nor­mal­ly in­stead of wait­ing for blind­ness to take over. And Chris­t­ian Guardi­no talked about how the treat­ment four years ago saved his sight, a span of time when the dark­ness might well have closed in.

This was no panacea. As the agency’s in­ter­nal re­view made clear, voreti­gene nepar­vovec (or Lux­tur­na) — which us­es an ade­no-as­so­ci­at­ed vi­ral vec­tor — im­proved sight us­ing the light lev­els mea­sured for the pri­ma­ry end­point, but fell far short of cur­ing reti­nal dy­s­tro­phy trig­gered by ge­net­ic RPE65 mu­ta­tions. Im­prove­ment in vi­sion is al­so lim­it­ed by the num­ber of vi­able reti­nal cells they have left at the time they’re treat­ed, ac­cord­ing to in­ves­ti­ga­tors.

Jeff Mar­raz­zo, Spark CEO

The pan­el ex­perts faced ques­tions about the dura­bil­i­ty of this eye ther­a­py, the pos­si­bil­i­ty that pa­tients will need mul­ti­ple treat­ments in or­der to pre­serve vi­sion gains, the right age to use it and the use of a com­plete­ly nov­el end­point for the pri­ma­ry goal when stan­dard vi­su­al acu­ity achieve­ments fell far short of the goal on sta­tis­ti­cal sig­nif­i­cance.

The ex­perts, though, seemed gen­er­al­ly im­pressed by the re­sults — with some reser­va­tions about the end­point — and sev­er­al were open to treat­ing very young pa­tients. Spark is sug­gest­ing three and old­er, and CEO Jeff Mar­raz­zo told me he was in­ter­est­ed in the en­cour­age­ment he heard to go even younger in some cas­es.

While a for­mal ap­proval is not guar­an­teed, it would be con­found­ing for the agency to ig­nore the pan­el and the ros­ter of pa­tients who came for­ward to talk about be­ing able to play, study and par­tic­i­pate in the kind of day-to-day ac­tiv­i­ties that had been de­nied them all their lives. An ap­proval here could well be the first of many to come, as a group of play­ers ad­vance treat­ments that use a be­nign virus to in­tro­duce a cor­rect­ed gene to fix a wide range of con­di­tions.

“It re­al­ly came to­geth­er in tri­an­gu­lat­ing a bunch of points,” Mar­raz­zo told me af­ter the land­mark vote came through, cit­ing not just the pa­tient tes­ti­mo­ny but al­so the physi­cians who were there to back up the ap­pli­ca­tion.

Mar­raz­zo isn’t of­fer­ing any price yet, and won’t un­til the ap­proval comes through. But it won’t be cheap. Es­ti­mates for one-time costs of­ten hov­er around the $1 mil­lion mark in gene ther­a­py. The CEO, who’s ob­vi­ous­ly thought quite a lot about it, says the clear path to en­sur­ing ac­cess un­der the cur­rent rules that gov­erns in­sur­ance points to a one-time charge per eye. It’s hard to of­fer an al­ter­na­tive mod­el, he adds, giv­en the kind of porta­bil­i­ty is­sues and pay­ment mod­els peo­ple have with their in­sur­ance cov­er­age to­day — but he’s in­ter­est­ed in ex­plor­ing it and see­ing what has to change to make that hap­pen.

Eigh­teen years ago, the gene ther­a­py field was near­ly shoved in­to obliv­ion af­ter the death of a pa­tient in a tri­al be­ing con­duct­ed by Penn’s James Wil­son. But over the past 10 years in­ves­ti­ga­tors, us­ing some of the same tech­nol­o­gy that Wil­son helped cre­ate, have mount­ed a mas­sive come­back ef­fort. In Spark’s case, the Chil­dren’s Hos­pi­tal of Philadel­phia played a key role in push­ing the ear­ly R&D work, giv­ing the biotech a big leg up in the race to get the first such gene ther­a­py in­to the US mar­ket.

There have been two oth­er gene ther­a­pies in Eu­rope, in­clud­ing Glax­o­SmithK­line’s Strimvelis. But they’ve been rarely used. The ques­tion now is how these treat­ments can get root­ed in the US mar­ket and then start to spread around the world.

That day looks much clos­er than it has ever been.

Kather­ine High, pres­i­dent and head of R&D at Spark Ther­a­peu­tics said:

The clin­i­cal pro­gram for Lux­tur­na in­cludes pa­tient da­ta that show ef­fi­ca­cy for up to four years on end­points in­clud­ing bi­lat­er­al mul­ti-lu­mi­nance mo­bil­i­ty test (MLMT) score change and full-field light sen­si­tiv­i­ty thresh­old (FST) test­ing, with ob­ser­va­tion on­go­ing. We look for­ward to con­tin­u­ing to work with FDA as it com­pletes its re­view of Lux­tur­na.

Grow­ing ac­cep­tance of ac­cel­er­at­ed path­ways for nov­el treat­ments: but does reg­u­la­to­ry ap­proval lead to com­mer­cial suc­cess?

By Mwango Kashoki, MD, MPH, Vice President-Technical, and Richard Macaulay, Senior Director, of Parexel Regulatory & Access

In recent years, we’ve seen a significant uptake in the use of regulatory options by companies looking to accelerate the journey of life-saving drugs to market. In 2018, 73% of the novel drugs approved by the U.S. Federal Drug Administration (FDA) were designated under one or more expedited development program categories (Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval).ᶦ

Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

As the world becomes increasingly dependant on Asia for the ingredients of its medicines, Sanofi sees business to be done in Europe.

The French drugmaker said it’s creating the world’s second largest active pharmaceutical ingredients (API) manufacturer by spinning out its six current sites into a standalone company: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France). They have mapped out €1 billion in expected sales by 2022 and 3,100 employees for the new operations headquartered in France.

UP­DAT­ED: NGM Bio takes leap for­ward in crowd­ed NASH field

South San Francisco-based NGM Bio may have underwhelmed with its interim analysis of a key cohort from a mid-stage NASH study last fall — but stellar topline data unveiled on Monday showed the compound induced significant signs of antifibrotic activity, NASH resolution and liver fat reduction, sending the company’s stock soaring.

There are an estimated 50+ companies focused on developing drugs for non-alcoholic steatohepatitis, or NASH, a common liver disease that has long flummoxed researchers. The first wave of NASH drug developers struggled with efficacy as well as safety — and companies big and small have crashed and burned.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.

Mickey Kertesz, KidsandArtOrg via YouTube

Soft­Bank's newest, $165M biotech in­vest­ment looks for in­fec­tious traces in the blood

SoftBank has found its newest biotech investment.

The Japanese bank has invested $165 million into Karius, a company that uses blood tests to diagnose infectious diseases, as part of its new Vision Fund 2. The full scope of the new fund has yet to be announced, but the first and newly-beleaguered Vision Fund poured $100 billion into technology companies, including the biotechs Vir Biotechnology and Roivant and the sequencing company 10x Genomics.

Methicillin-resistant Staph aureus (Shutterstock)

FDA grants ‘break­through’ sta­tus to an­tibi­ot­ic al­ter­na­tive as Con­tra­Fect rush­es to join fight against su­per­bug

An experimental drug that promises to be the first anti-infective agent to prove superior to vancomycin — an antibiotic approved in 1958 — has notched the FDA’s “breakthrough” status.

ContraFect said the designation was based on Phase II data in which exebacase was tested against a superbug known as methicillin-resistant Staph aureus, or MRSA. In a subgroup analysis, the clinical responder rate at day 14 was 42.8% higher than that among those treated with standard of care, the company said (p=0.010).

Zhong Nanshan, CGTN via YouTube

Har­vard joins coro­n­avirus fight with $115 mil­lion and a high-pro­file Chi­nese part­ner

For two months, as the novel coronavirus swelled from a few early cases tied to a Wuhan market to a global epidemic, most of the world’s focus and dollars have flowed toward emergency initiatives: building vaccines at a record pace, plucking experimental antivirals out of freezers to see what sticks and immunizing mice for new antibodies.

Now a new and well-funded collaboration between Harvard and a top Chinese research institute will play the long game. In a 5-year, $115 million initiative backed by China Evergrande Group, researchers from the Harvard Medical School, Harvard T.H. Chan School of Public Health and Guangzhou Institute for Respiratory Health will study the virus in an effort to develop therapies against infections by the novel coronavirus, known as SARS–CoV-2, and to prevent new ones.

No­var­tis gets a boost in block­buster mul­ti­ple scle­ro­sis race with Roche

In the first step of what’s likely to be a long and uphill battle for the drugmaker, the FDA has accepted Novartis’s BLA submission for a new multiple sclerosis drug and given it priority review. The PDUFA date for the potential blockbuster drug is in June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.

Juergen Horn

An­i­mal health vet Juer­gen Horn makes new an­ti­body play for pets, rak­ing $15M in Se­ries A haul

Zoetis forked over $85 million in 2017 to acquire Nexvet Biopharma and its pipeline of monoclonal antibodies. Juergen Horn, Nexvet’s former chief product development officer, has now secured $15 million for his own biologic company for animals: Invetx.

Buoyed by emerging advances in gene therapies for humans, scientists have started looking at harnessing the technology for animals setting up companies such as Penn-partnered Scout Bio and George Church-founded Rejuvenate Bio. But akin to Nexvet, Invetx is working on leveraging the time-tested science of monoclonal antibodies to treat chronic diseases that afflict man’s best friend.

As coro­n­avirus out­break reach­es 'tip­ping point,' GSK lends ad­ju­vant tech to Chi­nese part­ner armed with pre­clin­i­cal vac­cine

As the coronavirus originating out of Wuhan spreads to South Korea, Italy and Iran, stoking already intense fears of a pandemic, GlaxoSmithKline has found another pair of trusted hands to place its adjuvant system. China’s Clover Biopharmaceuticals will add the adjuvant to its preclinical, protein-based vaccine candidate against SARS-CoV-2.

Clover, which is based in the inland city of Chengdu, boasts of a platform dubbed Trimer-Tag that produces covalently-trimerized fusion proteins. Its candidate, COVID-19 S-Trimer, resembles the viral spike (S)-protein found in the virus.